Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
Add more filters










Publication year range
1.
J Neurochem ; 160(6): 643-661, 2022 03.
Article in English | MEDLINE | ID: mdl-34935149

ABSTRACT

Multiple sclerosis (MS), especially in its progressive phase, involves early axonal and neuronal damage resulting from a combination of inflammatory mediators, demyelination, and loss of trophic support. During progressive disease stages, a microenvironment is created within the central nervous system (CNS) favoring the arrival and retention of inflammatory cells. Active demyelination and neurodegeneration have also been linked to microglia (MG) and astrocyte (AST)-activation in early lesions. While reactive MG can damage tissue, exacerbate deleterious effects, and contribute to neurodegeneration, it should be noted that activated MG possess neuroprotective functions as well, including debris phagocytosis and growth factor secretion. The progressive form of MS can be modeled by the prolonged administration to cuprizone (CPZ) in adult mice, as CPZ induces highly reproducible demyelination of different brain regions through oligodendrocyte (OLG) apoptosis, accompanied by MG and AST activation and axonal damage. Therefore, our goal was to evaluate the effects of a reduction in microglial activation through orally administered brain-penetrant colony-stimulating factor-1 receptor (CSF-1R) inhibitor BLZ945 (BLZ) on neurodegeneration and its correlation with demyelination, astroglial activation, and behavior in a chronic CPZ-induced demyelination model. Our results show that BLZ treatment successfully reduced the microglial population and myelin loss. However, no correlation was found between myelin preservation and neurodegeneration, as axonal degeneration was more prominent upon BLZ treatment. Concomitantly, BLZ failed to significantly offset CPZ-induced astroglial activation and behavioral alterations. These results should be taken into account when proposing the modulation of microglial activation in the design of therapies relevant for demyelinating diseases. Cover Image for this issue: https://doi.org/10.1111/jnc.15394.


Subject(s)
Demyelinating Diseases , Multiple Sclerosis , Animals , Colony-Stimulating Factors/adverse effects , Colony-Stimulating Factors/metabolism , Cuprizone/metabolism , Cuprizone/toxicity , Demyelinating Diseases/chemically induced , Demyelinating Diseases/drug therapy , Demyelinating Diseases/metabolism , Disease Models, Animal , Mice , Mice, Inbred C57BL , Microglia/metabolism , Multiple Sclerosis/metabolism , Myelin Sheath/metabolism
2.
J Neuroendocrinol ; 30(11): e12649, 2018 11.
Article in English | MEDLINE | ID: mdl-30303567

ABSTRACT

Changes of neurosteroids may be involved in the pathophysiology of multiple sclerosis (MS). The present study investigated whether changes of neurosteroidogenesis also occurred in the grey and white matter regions of the brain in mice subjected to cuprizone-induced demyelination. Accordingly, we compared the expression of neurosteroidogenic proteins, including steroidogenic acute regulatory protein (StAR), voltage-dependent anion channel (VDAC) and 18 kDa translocator protein (TSPO), as well as neurosteroidogenic enzymes, including the side chain cleavage enzyme (P450scc), 3ß-hydroxysteroid dehydrogenase/isomerase and 5α-reductase (5α-R), during the demyelination and remyelination periods. Using immunohistochemistry and a quantitative polymerase chain reaction, we demonstrated a decreased expression of StAR, P450scc and 5α-R with respect to an increase astrocytic and microglial reaction and elevated levels of tumor necrosis factor (TNF)α during the cuprizone demyelination period in the hippocampus, cortex and corpus callosum. These parameters, as well as the glial reaction, were normalised after 2 weeks of spontaneous remyelination in regions containing grey matter. Conversely, persistent elevated levels of TNFα and low levels of StAR and P450scc were observed during remyelination in corpus callosum white matter. We conclude that neurosteroidogenesis/myelination status and glial reactivity are inversely related in the hippocampus and neocortex. Establishing a cause and effect relationship for the measured variables remains a future challenge for understanding the pathophysiology of MS.


Subject(s)
Brain/enzymology , Brain/metabolism , Myelin Sheath/enzymology , Myelin Sheath/metabolism , Remyelination , 3-Hydroxysteroid Dehydrogenases/metabolism , Animals , Brain/drug effects , Cholestenone 5 alpha-Reductase/metabolism , Cuprizone/administration & dosage , Cytochrome P-450 Enzyme System/metabolism , Disease Models, Animal , Female , Mice, Inbred C57BL , Multiple Sclerosis/chemically induced , Multiple Sclerosis/enzymology , Multiple Sclerosis/metabolism , Myelin Sheath/drug effects , Neuroglia/drug effects , Neuroglia/enzymology , Neuroglia/metabolism , Phosphoproteins/metabolism , Receptors, GABA/metabolism , Remyelination/drug effects , Voltage-Dependent Anion Channel 1/metabolism
3.
J Neurochem ; 142(2): 323-337, 2017 07.
Article in English | MEDLINE | ID: mdl-28498493

ABSTRACT

Glaucoma is a leading cause of blindness, characterized by retinal ganglion cell (RGC) loss and optic nerve (ON) damage. Cumulative evidence suggests glial cell involvement in the degeneration of the ON and RGCs. We analyzed the contribution of microglial reactivity to early axoglial alterations of the ON in an induced model of ocular hypertension. For this purpose, vehicle or chondroitin sulfate (CS) were weekly injected into the eye anterior chamber from Wistar rats for different intervals. The amount of Brn3a(+) RGC significantly decreased in CS-injected eyes for 10 and 15 (but not 6) weeks. A reduction in anterograde transport of ß-subunit cholera toxin was observed in the superior colliculus and the lateral geniculate nucleus contralateral to CS-injected eyes for 6 and 15 weeks. A disruption of cholera toxin ß-subunit transport was observed at the proximal myelinated ON. A significant decrease in phosphorylated neurofilament heavy chain immunoreactivity, an increase in ionized calcium-binding adaptor molecule 1(+), ED1(+) (microglial markers), and glial fibrillary acidic protein (astrocytes) (+) area, and decreased luxol fast blue staining were observed in the ON at 6 and 15 weeks of ocular hypertension. Microglial reactivity involvement was examined through a daily treatment with minocycline (30 mg/kg, i.p.) for 2 weeks, after 4 weeks of ocular hypertension. Minocycline prevented the increase in ionized calcium-binding adaptor molecule 1(+), ED-1(+), and glial fibrillary acidic protein(+) area, the decrease in phosphorylated neurofilament heavy-chain immunoreactivity and luxol fast blue staining, and the deficit in anterograde transport induced by 6 weeks of ocular hypertension. Thus, targeting microglial reactivity might prevent early axoglial alterations in the glaucomatous ON. Cover Image for this issue: doi: 10.1111/jnc.13807.


Subject(s)
Glaucoma/drug therapy , Optic Nerve/drug effects , Animals , Astrocytes/drug effects , Astrocytes/metabolism , Disease Models, Animal , Geniculate Bodies/drug effects , Glaucoma/metabolism , Male , Microglia/drug effects , Microglia/metabolism , Minocycline/administration & dosage , Minocycline/pharmacology , Neuroglia/drug effects , Neuroglia/metabolism , Optic Nerve/metabolism , Rats, Wistar , Retina/drug effects , Retina/metabolism
5.
Neurobiol Dis ; 96: 127-143, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27612409

ABSTRACT

Galectin-1 (Gal-1), a member of a highly conserved family of animal lectins, binds to the common disaccharide [Galß(1-4)-GlcNAc] on both N- and O-glycans decorating cell surface glycoconjugates. Current evidence supports a role for Gal-1 in the pathophysiology of multiple sclerosis (MS), one of the most prevalent chronic inflammatory diseases. Previous studies showed that Gal-1 exerts neuroprotective effects by promoting microglial deactivation in a model of autoimmune neuroinflammation and induces axonal regeneration in spinal cord injury. Seeking a model that could link demyelination, oligodendrocyte (OLG) responses and microglial activation, here we used a lysolecithin (LPC)-induced demyelination model to evaluate the ability of Gal-1 to preserve myelin without taking part in T-cell modulation. Gal-1 treatment after LPC-induced demyelination promoted a significant decrease in the demyelinated area and fostered more efficient remyelination, concomitantly with an attenuated oligodendroglial progenitor response reflecting less severe myelination damage. These results were accompanied by a decrease in the area of microglial activation with a shift toward an M2-polarized microglial phenotype and diminished astroglial activation. In vitro studies further showed that, mechanistically, Gal-1 targets activated microglia, promoting an increase in their myelin phagocytic capacity and their shift toward an M2 phenotype, and leads to oligodendroglial differentiation. Therefore, this study supports the use of Gal-1 as a potential treatment for demyelinating diseases such as MS.


Subject(s)
Cell Differentiation/drug effects , Demyelinating Diseases , Galectin 1/pharmacology , Galectin 1/therapeutic use , Microglia/drug effects , Oligodendroglia/drug effects , Phagocytosis/drug effects , 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase/genetics , 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase/metabolism , Animals , Animals, Newborn , Brain/drug effects , Brain/ultrastructure , Cell Polarity/drug effects , Demyelinating Diseases/chemically induced , Demyelinating Diseases/drug therapy , Demyelinating Diseases/pathology , Disease Models, Animal , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Lysophosphatidylcholines/toxicity , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microglia/ultrastructure , Nerve Tissue Proteins/metabolism , Oligodendroglia/ultrastructure , Tissue Culture Techniques
6.
Exp Neurol ; 283(Pt A): 165-78, 2016 09.
Article in English | MEDLINE | ID: mdl-27296316

ABSTRACT

UNLABELLED: Axonal growth cone collapse following spinal cord injury (SCI) is promoted by semaphorin3A (Sema3A) signaling via PlexinA4 surface receptor. This interaction triggers intracellular signaling events leading to increased hydrogen peroxide levels which in turn promote filamentous actin (F-actin) destabilization and subsequent inhibition of axonal re-growth. In the current study, we demonstrated that treatment with galectin-1 (Gal-1), in its dimeric form, promotes a decrease in hydrogen peroxide (H2O2) levels and F-actin repolimerization in the growth cone and in the filopodium of neuron surfaces. This effect was dependent on the carbohydrate recognition activity of Gal-1, as it was prevented using a Gal-1 mutant lacking carbohydrate-binding activity. Furthermore, Gal-1 promoted its own active ligand-mediated endocytosis together with the PlexinA4 receptor, through mechanisms involving complex branched N-glycans. In summary, our results suggest that Gal-1, mainly in its dimeric form, promotes re-activation of actin cytoskeleton dynamics via internalization of the PlexinA4/Gal-1 complex. This mechanism could explain, at least in part, critical events in axonal regeneration including the full axonal re-growth process, de novo formation of synapse clustering, axonal re-myelination and functional recovery of coordinated locomotor activities in an in vivo acute and chronic SCI model. SIGNIFICANCE STATEMENT: Axonal regeneration is a response of injured nerve cells critical for nerve repair in human spinal cord injury. Understanding the molecular mechanisms controlling nerve repair by Galectin-1, may be critical for therapeutic intervention. Our results show that Galectin-1; in its dimeric form, interferes with hydrogen peroxide production triggered by Semaphorin3A. The high levels of this reactive oxygen species (ROS) seem to be the main factor preventing axonal regeneration due to promotion of actin depolymerization at the axonal growth cone. Thus, Galectin-1 administration emerges as a novel therapeutic modality for promoting nerve repair and preventing axonal loss.


Subject(s)
Actins/metabolism , Axons/physiology , Endocytosis/physiology , Galectin 1/metabolism , Hydrogen Peroxide/metabolism , Nerve Regeneration/physiology , Neurons/metabolism , Animals , Axons/drug effects , Cells, Cultured , Disease Models, Animal , Embryo, Mammalian , Endocytosis/drug effects , Galectin 1/genetics , Galectin 1/pharmacology , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Hippocampus/cytology , Ligands , Mice , Mice, Inbred C57BL , Mice, Knockout , Motor Activity/genetics , N-Acetylglucosaminyltransferases/genetics , N-Acetylglucosaminyltransferases/metabolism , Nerve Regeneration/drug effects , Nerve Regeneration/genetics , Neurons/cytology , Neurons/drug effects , Pseudopodia/drug effects , Pseudopodia/physiology , Rats , Semaphorin-3A/pharmacology , Signal Transduction , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/pathology
7.
FEBS Lett ; 589(22): 3388-95, 2015 Nov 14.
Article in English | MEDLINE | ID: mdl-26296311

ABSTRACT

Considering the worldwide incidence of well characterized demyelinating disorders such as Multiple Sclerosis (MS) and the increasing number of pathologies recently found to involve hypomyelinating factors such as micronutrient deficits, elucidating the molecular basis of central nervous system (CNS) demyelination, remyelination and hypomyelination becomes essential to the development of future neuroregenerative therapies. In this context, this review discusses novel findings on the contribution of galectin-3 (Gal-3), transferrin (Tf) and iron to the processes of myelination and remyelination and their potentially positive regulation of oligodendroglial precursor cell (OPC) differentiation. Studies were conducted in cuprizone (CPZ)-induced demyelination and iron deficiency (ID)-induced hypomyelination, and the participation of glial and neural stem cells (NSC) in the remyelination process was evaluated by means of both in vivo and in vitro assays on primary cell cultures.


Subject(s)
Galectin 3/metabolism , Iron/metabolism , Myelin Sheath/physiology , Transferrin/metabolism , Animals , Cuprizone/pharmacology , Demyelinating Diseases/metabolism , Demyelinating Diseases/physiopathology , Humans , Myelin Sheath/drug effects
8.
J Neurochem ; 133(1): 113-24, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25565274

ABSTRACT

The principal motor tract involved in mammalian locomotor activities is known as the corticospinal tract (CST), which starts in the brain motor cortex (upper motor neuron), extends its axons across the brain to brainstem and finally reaches different regions of spinal cord, contacting the lower motor neurons. Visualization of the CST is essential to carry out studies in different kinds of pathologies such as spinal cord injury or multiple sclerosis. At present, most studies of axon structure and/or integrity that involve histological tissue sectioning present the problem of finding the region where the CST is predominant. To solve this problem, one could use a novel technique to make the tissues transparent and observe them directly without histological sectioning. However, the disadvantage of this procedure is the need of costly and nonconventional equipment, such as two-photon fluorescence microscopy or ultramicroscopy to perform the image acquisition. Here, we show that labeling the CST with FluoroRuby in the motor cortex and then performing the clearing technique, the z-acquisition of the entire CST in unsectioned tissue followed by three-dimensional reconstruction can be carried out by standard one-photon confocal microscopy, with yields similar to those obtained by two-photon microscopy. In addition, we present an example of the application of this method in a spinal cord injury model, where the disruption of CST is shown at the lesion site.


Subject(s)
Axons/pathology , Pyramidal Tracts/pathology , Spinal Cord Injuries/pathology , Animals , Brain/pathology , Image Processing, Computer-Assisted , Imaging, Three-Dimensional , Male , Mice , Mice, Inbred C57BL , Microscopy, Confocal , Motor Cortex/pathology , Pyramidal Cells/pathology
9.
Medicina (B Aires) ; 74(4): 321-5, 2014.
Article in Spanish | MEDLINE | ID: mdl-25188662

ABSTRACT

When spinal cord injury (SCI) occurs, a great number of inhibitors of axonal regeneration consecutively invade the injured site. The first protein to reach the lesion is known as semaphorin 3A (Sema3A), which serves as a powerful inhibitor of axonal regeneration. Mechanistically binding of Sem3A to the neuronal receptor complex neuropilin-1 (NRP-1) / PlexinA4 prevents axonal regeneration. In this special article we review the effects of galectin-1 (Gal-1), an endogenous glycan-binding protein, abundantly present at inflammation and injury sites. Notably, Gal1 adheres selectively to the NRP-1/PlexinA4 receptor complex in injured neurons through glycan-dependent mechanisms, interrupts the Sema3A pathway and contributes to axonal regeneration and locomotor recovery after SCI. While both the monomeric and dimeric forms of Gal-1 contribute to "switch-off" classically-activated microglia, only dimeric Gal-1 binds to the NRP-1/PlexinA4 receptor complex and promotes axonal regeneration. Thus, dimeric Gal-1 promotes functional recovery of spinal lesions by interfering with inhibitory signals triggered by Sema3A adhering to the NRP-1/PlexinA4 complex, supporting the use of dimeric Gal-1 for the treatment of SCI patients.


Subject(s)
Axons/physiology , Galectin 1/physiology , Nerve Regeneration/physiology , Spinal Cord Injuries/physiopathology , Animals , Humans , Mice , Microglia/metabolism , Nerve Tissue Proteins/metabolism , Neuropilin-1/metabolism , Receptors, Cell Surface/metabolism , Semaphorin-3A/physiology
10.
Medicina (B.Aires) ; 74(4): 321-325, ago. 2014. ilus
Article in Spanish | LILACS | ID: lil-734393

ABSTRACT

Al producirse una lesión de médula espinal (LME), un sinnúmero de proteínas inhibidoras de la regeneración axonal ocupan el sitio de lesión en forma secuencial. La primer proteína en llegar al mismo se conoce como semaforina 3A (Sema3A), siendo además una de las más potentes por su acción de inhibir la regeneración axonal. A nivel mecanístico la unión de esta proteína al complejo-receptor neuronal neuropilin-1 (NRP-1)/PlexinA4 evita que se produzca regeneración axonal. En este trabajo de revisión se discutirá la acción de galectin-1 (Gal-1), una proteína endógena de unión a glicanos, que selectivamente se une al complejo-receptor NRP-1/PlexinA4 de las neuronas lesionadas a través de un mecanismo dependiente de interacciones lectina-glicano, interrumpiendo la señalización generada por Sema3A y permitiendo de esta manera la regeneración axonal y recuperación locomotora luego de producirse la LME. Mientras ambas formas de Gal-1 (monomérica y dimérica) contribuyen a la inactivación de la microglia, solo la forma dimérica de Gal-1 es capaz de unirse al complejo-receptor NRP-1/PlexinA4 y promover regeneración axonal. Por lo tanto, Gal-1 dimérica produce recuperación de las lesiones espinales interfiriendo en la señalización de Sema3A a través de la unión al complejo-receptor NRP-1/PlexinA4, sugiriendo el uso de esta lectina en su forma dimérica para el tratamiento de pacientes con LME.


When spinal cord injury (SCI) occurs, a great number of inhibitors of axonal regeneration consecutively invade the injured site. The first protein to reach the lesion is known as semaphorin 3A (Sema3A), which serves as a powerful inhibitor of axonal regeneration. Mechanistically binding of Sem3A to the neuronal receptor complex neuropilin-1 (NRP-1) / PlexinA4 prevents axonal regeneration. In this special article we review the effects of galectin-1 (Gal-1), an endogenous glycan-binding protein, abundantly present at inflammation and injury sites. Notably, Gal1 adheres selectively to the NRP-1/PlexinA4 receptor complex in injured neurons through glycan-dependent mechanisms, interrupts the Sema3A pathway and contributes to axonal regeneration and locomotor recovery after SCI. While both the monomeric and dimeric forms of Gal-1 contribute to ’switch-off’ classically-activated microglia, only dimeric Gal-1 binds to the NRP-1/PlexinA4 receptor complex and promotes axonal regeneration. Thus, dimeric Gal-1 promotes functional recovery of spinal lesions by interfering with inhibitory signals triggered by Sema3A adhering to the NRP-1/PlexinA4 complex, supporting the use of dimeric Gal-1 for the treatment of SCI patients.


Subject(s)
Animals , Humans , Mice , Axons/physiology , Galectin 1/physiology , Nerve Regeneration/physiology , Spinal Cord Injuries/physiopathology , Microglia/metabolism , Nerve Tissue Proteins/metabolism , Neuropilin-1/metabolism , Receptors, Cell Surface/metabolism , /physiology
11.
Medicina (B.Aires) ; 74(4): 321-325, ago. 2014. ilus
Article in Spanish | BINACIS | ID: bin-131434

ABSTRACT

Al producirse una lesión de médula espinal (LME), un sinnúmero de proteínas inhibidoras de la regeneración axonal ocupan el sitio de lesión en forma secuencial. La primer proteína en llegar al mismo se conoce como semaforina 3A (Sema3A), siendo además una de las más potentes por su acción de inhibir la regeneración axonal. A nivel mecanístico la unión de esta proteína al complejo-receptor neuronal neuropilin-1 (NRP-1)/PlexinA4 evita que se produzca regeneración axonal. En este trabajo de revisión se discutirá la acción de galectin-1 (Gal-1), una proteína endógena de unión a glicanos, que selectivamente se une al complejo-receptor NRP-1/PlexinA4 de las neuronas lesionadas a través de un mecanismo dependiente de interacciones lectina-glicano, interrumpiendo la señalización generada por Sema3A y permitiendo de esta manera la regeneración axonal y recuperación locomotora luego de producirse la LME. Mientras ambas formas de Gal-1 (monomérica y dimérica) contribuyen a la inactivación de la microglia, solo la forma dimérica de Gal-1 es capaz de unirse al complejo-receptor NRP-1/PlexinA4 y promover regeneración axonal. Por lo tanto, Gal-1 dimérica produce recuperación de las lesiones espinales interfiriendo en la señalización de Sema3A a través de la unión al complejo-receptor NRP-1/PlexinA4, sugiriendo el uso de esta lectina en su forma dimérica para el tratamiento de pacientes con LME.(AU)


When spinal cord injury (SCI) occurs, a great number of inhibitors of axonal regeneration consecutively invade the injured site. The first protein to reach the lesion is known as semaphorin 3A (Sema3A), which serves as a powerful inhibitor of axonal regeneration. Mechanistically binding of Sem3A to the neuronal receptor complex neuropilin-1 (NRP-1) / PlexinA4 prevents axonal regeneration. In this special article we review the effects of galectin-1 (Gal-1), an endogenous glycan-binding protein, abundantly present at inflammation and injury sites. Notably, Gal1 adheres selectively to the NRP-1/PlexinA4 receptor complex in injured neurons through glycan-dependent mechanisms, interrupts the Sema3A pathway and contributes to axonal regeneration and locomotor recovery after SCI. While both the monomeric and dimeric forms of Gal-1 contribute to ’switch-off’ classically-activated microglia, only dimeric Gal-1 binds to the NRP-1/PlexinA4 receptor complex and promotes axonal regeneration. Thus, dimeric Gal-1 promotes functional recovery of spinal lesions by interfering with inhibitory signals triggered by Sema3A adhering to the NRP-1/PlexinA4 complex, supporting the use of dimeric Gal-1 for the treatment of SCI patients.(AU)

12.
Medicina (B Aires) ; 74(4): 321-5, 2014.
Article in Spanish | BINACIS | ID: bin-133492

ABSTRACT

When spinal cord injury (SCI) occurs, a great number of inhibitors of axonal regeneration consecutively invade the injured site. The first protein to reach the lesion is known as semaphorin 3A (Sema3A), which serves as a powerful inhibitor of axonal regeneration. Mechanistically binding of Sem3A to the neuronal receptor complex neuropilin-1 (NRP-1) / PlexinA4 prevents axonal regeneration. In this special article we review the effects of galectin-1 (Gal-1), an endogenous glycan-binding protein, abundantly present at inflammation and injury sites. Notably, Gal1 adheres selectively to the NRP-1/PlexinA4 receptor complex in injured neurons through glycan-dependent mechanisms, interrupts the Sema3A pathway and contributes to axonal regeneration and locomotor recovery after SCI. While both the monomeric and dimeric forms of Gal-1 contribute to "switch-off" classically-activated microglia, only dimeric Gal-1 binds to the NRP-1/PlexinA4 receptor complex and promotes axonal regeneration. Thus, dimeric Gal-1 promotes functional recovery of spinal lesions by interfering with inhibitory signals triggered by Sema3A adhering to the NRP-1/PlexinA4 complex, supporting the use of dimeric Gal-1 for the treatment of SCI patients.

13.
Glia ; 60(10): 1540-54, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22736466

ABSTRACT

Our previous studies showed that the intracerebral injection of apotransferrin (aTf) attenuates white matter damage and accelerates the remyelination process in a neonatal rat model of cerebral hypoxia-ischemia (HI) injury. However, the intracerebral injection of aTf might not be practical for clinical treatments. Therefore, the development of less invasive techniques capable of delivering aTf to the central nervous system would clearly aid in its effective clinical use. In this work, we have determined whether intranasal (iN) administration of human aTf provides neuroprotection to the neonatal mouse brain following a cerebral hypoxic-ischemic event. Apotransferrin was infused into the naris of neonatal mice and the HI insult was induced by right common carotid artery ligation followed by exposure to low oxygen concentration. Our results showed that aTf was successfully delivered into the neonatal HI brain and detected in the olfactory bulb, forebrain and posterior brain 30 min after inhalation. This treatment successfully reduced white matter damage, neuronal loss and astrogliosis in different brain regions and enhanced the proliferation and survival of oligodendroglial progenitor cells (OPCs) in the subventricular zone and corpus callosum (CC). Additionally, using an in vitro hypoxic model, we demonstrated that aTf prevents oligodendrocyte progenitor cell death by promoting their differentiation. In summary, these data suggest that iN administration of aTf has the potential to be used for clinical treatment to protect myelin and to induce remyelination in demyelinating hypoxic-ischemic events in the neonatal brain.


Subject(s)
Apoproteins/administration & dosage , Brain Injuries/prevention & control , Hypoxia-Ischemia, Brain/pathology , Nerve Fibers, Myelinated/drug effects , Neuroprotective Agents/administration & dosage , Transferrin/administration & dosage , 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase/genetics , Administration, Intranasal , Age Factors , Animals , Animals, Newborn , Antigens/metabolism , Autophagy-Related Proteins , Brain Injuries/etiology , Bromodeoxyuridine/metabolism , Caspase 3/metabolism , Cell Death/drug effects , Cell Death/genetics , Cell Proliferation/drug effects , Cells, Cultured , Cerebral Cortex/cytology , Colchicine/pharmacology , Corpus Callosum/drug effects , Corpus Callosum/pathology , Cytochalasin B/pharmacology , Female , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Green Fluorescent Proteins/genetics , Humans , Hypoxia/drug therapy , Hypoxia-Ischemia, Brain/complications , Hypoxia-Ischemia, Brain/drug therapy , Intermediate Filament Proteins/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Lateral Ventricles/drug effects , Lateral Ventricles/physiology , Male , Mice , Mice, Transgenic , Myelin Basic Protein/metabolism , Nerve Fibers, Myelinated/metabolism , Nerve Tissue Proteins/metabolism , Nestin , Neurogenesis/drug effects , Oligodendroglia/drug effects , Platelet-Derived Growth Factor/metabolism , Proteoglycans/metabolism , SOXB1 Transcription Factors/metabolism , Time Factors
14.
PLoS One ; 7(12): e51966, 2012.
Article in English | MEDLINE | ID: mdl-23284834

ABSTRACT

Diabetic retinopathy is a leading cause of blindness. Visual function disorders have been demonstrated in diabetics even before the onset of retinopathy. At early stages of experimental diabetes, axoglial alterations occur at the distal portion of the optic nerve. Although ischemic conditioning can protect neurons and synaptic terminals against ischemic damage, there is no information on its ability to protect axons. We analyzed the effect of ischemic conditioning on the early axoglial alterations in the distal portion of the optic nerve induced by experimental diabetes. Diabetes was induced in Wistar rats by an intraperitoneal injection of streptozotocin. Retinal ischemia was induced by increasing intraocular pressure to 120 mm Hg for 5 min; this maneuver started 3 days after streptozotocin injection and was weekly repeated in one eye, while the contralateral eye was submitted to a sham procedure. The application of ischemia pulses prevented a deficit in the anterograde transport from the retina to the superior colliculus, as well as an increase in astrocyte reactivity, ultraestructural myelin alterations, and altered morphology of oligodendrocyte lineage in the optic nerve distal portion at early stages of experimental diabetes. Ischemia tolerance prevented a significant decrease of retinal glutamine synthetase activity induced by diabetes. These results suggest that early vision loss in diabetes could be abated by ischemic conditioning which preserved axonal function and structure.


Subject(s)
Diabetic Retinopathy/pathology , Ischemic Preconditioning , Optic Nerve/blood supply , Optic Nerve/pathology , Retinal Ganglion Cells/pathology , Visual Pathways/blood supply , Visual Pathways/pathology , Animals , Astrocytes/metabolism , Axons/ultrastructure , Biological Transport , Blood Glucose , Body Weight , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Diabetic Retinopathy/metabolism , Diabetic Retinopathy/prevention & control , Enzyme Activation , Glutamate-Ammonia Ligase , Male , Oligodendroglia/metabolism , Rats , Retina/metabolism , Superior Colliculi/metabolism , Time Factors , Transcription Factor Brn-3A/metabolism
15.
Am J Pathol ; 180(1): 303-13, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22079928

ABSTRACT

Diabetic retinopathy is a leading cause of acquired blindness. Visual function disorders have been observed in diabetic patients with very early retinopathy or even before the onset of retinopathy. The aim of the present work was to analyze the visual pathway in an early stage of experimental diabetes. Diabetes was induced in Wistar rats by an i.p. injection of streptozotocin. A deficit in anterograde transport from the retina to the superior colliculus was observed 6 weeks after streptozotocin injection. At this time point, morphologic studies did not reveal retinal ganglion cell loss or substantial alterations in the superior colliculus. The optic nerve was morphometrically evaluated at intraorbital (unmyelinated and myelinated) and intracranial sections. In animals that had been diabetic for 6 weeks, a large increase in astrocyte reactivity occurred in the distal (but not the intraorbital) portion, which coincided with significant axon loss. Moreover, profound myelin alterations and altered morphologic features of oligodendrocyte lineage were observed at the distal (but not the proximal) optic nerve portion. The present results suggest that axoglial alterations at the distal portion of the optic nerve could be the first structural change in the diabetic visual pathway.


Subject(s)
Axons/physiology , Diabetes Mellitus, Experimental/physiopathology , Diabetic Neuropathies/physiopathology , Diabetic Retinopathy/physiopathology , Visual Pathways/physiology , Animals , Axons/ultrastructure , Cell Count , Cholera Toxin , Coloring Agents , Diabetes Mellitus, Experimental/pathology , Diabetic Neuropathies/pathology , Diabetic Retinopathy/pathology , Male , Microscopy, Electron , Rats , Rats, Wistar , Retinal Ganglion Cells/physiology , Retinal Ganglion Cells/ultrastructure
16.
ASN Neuro ; 2(5): e00048, 2010 Nov 19.
Article in English | MEDLINE | ID: mdl-21113232

ABSTRACT

We have previously demonstrated that aTf (apotransferrin) accelerates maturation of OLs (oligodendrocytes) in vitro as well as in vivo. The purpose of this study is to determine whether aTf plays a functional role in a model of H/I (hypoxia/ischaemia) in the neonatal brain. Twenty-four hours after H/I insult, neonatal rats were intracranially injected with aTf and the effects of this treatment were evaluated in the CC (corpus callosum) as well as the SVZ (subventricular zone) at different time points. Similar to previous studies, the H/I event produced severe demyelination in the CC. Demyelination was accompanied by microglial activation, astrogliosis and iron deposition. Ferritin levels increased together with lipid peroxidation and apoptotic cell death. Histological examination after the H/I event in brain tissue of aTf-treated animals (H/I aTF) revealed a great number of mature OLs repopulating the CC compared with saline-treated animals (H/I S). ApoTf treatment induced a gradual increase in MBP (myelin basic protein) and myelin lipid staining in the CC reaching normal levels after 15 days. Furthermore, significant increase in the number of OPCs (oligodendroglial progenitor cells) was found in the SVZ of aTf-treated brains compared with H/I S. Specifically, there was a rise in cells positive for OPC markers, i.e. PDGFRα and SHH(+) cells, with a decrease in cleaved-caspase-3(+) cells compared with H/I S. Additionally, neurospheres from aTf-treated rats were bigger in size and produced more O4/MBP(+) cells. Our findings indicate a role for aTf as a potential inducer of OLs in neonatal rat brain in acute demyelination caused by H/I and a contribution to the differentiation/maturation of OLs and survival/migration of SVZ progenitors after demyelination in vivo.


Subject(s)
Apoproteins/physiology , Hypoxia-Ischemia, Brain/pathology , Hypoxia-Ischemia, Brain/prevention & control , Myelin Sheath/metabolism , Myelin Sheath/pathology , Recovery of Function/physiology , Transferrin/physiology , Animals , Animals, Newborn , Apoproteins/therapeutic use , Cells, Cultured , Corpus Callosum/pathology , Corpus Callosum/physiology , Female , Humans , Hypoxia-Ischemia, Brain/physiopathology , Male , Myelin Sheath/physiology , Neural Stem Cells/pathology , Neural Stem Cells/physiology , Oligodendroglia/pathology , Oligodendroglia/physiology , Rats , Rats, Wistar , Transferrin/therapeutic use
17.
Phytochemistry ; 68(8): 1139-46, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17399749

ABSTRACT

In order to examine the possible involvement of the 20S proteasome in degradation of oxidized proteins, the effects of different cadmium concentrations on its activities, protein abundance and oxidation level were studied using maize (Zea mays L.) leaf segments. The accumulation of carbonylated and ubiquitinated proteins was also investigated. Treatment with 50 microM CdCl(2) increased both trypsin- and PGPH-like activities of the 20S proteasome. The incremental changes in 20S proteasome activities were probably caused by an increased level of 20S proteasome oxidation, with this being responsible for degradation of the oxidized proteins. When leaf segments were treated with 100 microM CdCl(2), the chymotrysin- and trypsin-like activities of the 20S proteasome also decreased, with a concomitant increase in accumulation of carbonylated and ubiquitinated proteins. With both Cd(2+) concentrations, the abundance of the 20S proteasome protein remained similar to the control experiments. These results provide evidence for the involvement of this proteolytic system in cadmium-stressed plants.


Subject(s)
Cadmium Chloride/pharmacology , Plant Proteins/metabolism , Proteasome Endopeptidase Complex/metabolism , Ubiquitin/metabolism , Zea mays/metabolism , Oxidation-Reduction/drug effects , Plant Leaves/drug effects , Plant Leaves/metabolism , Proteasome Endopeptidase Complex/drug effects , Proteasome Endopeptidase Complex/physiology , Zea mays/drug effects
18.
Plant Sci ; 171(4): 531-7, 2006 Oct.
Article in English | MEDLINE | ID: mdl-25193651

ABSTRACT

The effect of oxidative stress induced by cadmium on growth parameters and on the balance between protein synthesis and degradation was studied in sunflower (Helianthus annuus L.) leaves. Plants were germinated for 10 days and then transferred to hydroponic medium devoid (control) or containing 100, 200 and 300µM CdCl2. Analyses were performed between days 0 and 4 of Cd-treatment. All Cd(2+) concentrations significantly reduced leaf area and, fresh and dry weight, but leaf relative water content only decreased with 200 and 300µM Cd(2+). Control and treated plants had similar soluble protein content and showed the same rate of soluble protein labeling under the assay conditions. Although protease activity increased with cadmium treatment, proteasome activity was significantly inhibited. Expression of 20S proteasome remained similar to controls in cadmium treated plants. Cadmium caused an increase in ubiquitin-conjugated proteins and carbonyl groups content of treated plants, compared to control values. Cadmium induced an increase in protease specific activity; nevertheless, this increase was not relevant enough to avoid accumulation of oxidized proteins. Oxidation of proteins is one of the most important effects of cadmium treatment. The results presented here provide evidence for the role of the proteolytic system in sunflower plants subjected to cadmium stress.

19.
J Neurosci Res ; 82(6): 822-30, 2005 Dec 15.
Article in English | MEDLINE | ID: mdl-16302188

ABSTRACT

Apotransferrin (aTf), has been shown to accelerate the differentiation of oligodendroglial cells (OLGcs) in primary cultures and to increase the expression of different components of the myelin cytoskeleton (CSK). We examined the incorporation and distribution of human aTf (aTfh) exogenously added to OLGcs cultures and its effects on the CSK of the OLGcs. When OLGcs treated with aTfh were extracted with a CSK-stabilizing buffer containing detergent, aTfh was found in the soluble fraction. In vitro experiments showed that purified tubulin was not altered by the addition of aTfh. In OLGc primary cultures treated with aTfh, this glycoprotein showed a punctate distribution pattern along the OLGc processes. Treatment of the cultures with colchicine, cytochalasin, or taxol induced a displacement of the immunoreactivity of aTfh toward the OLGc soma. Analysis of the effects of aTfh on the cell distribution of tyrosinated and detyrosinated tubulin and STOP (stable tubule only polypeptide), showed that aTfh added to OLGc cultures promoted changes suggesting a stabilizing effect on the microtubules (MT) at the tip of the processes. Kinesin and dynein were found to colocalize with the aTfh, indicating that these motors participate in the transport of the added glycoprotein. Moreover, after treatment with aTfh, clathrin immunoreactivity was displaced from the OLGc body toward the cell processes. These results indicate that although aTfh added to OLGcs does not interact directly with CSK components, it seems to be transported in clathrin coated vesicles from the cell body to the tips of the OLGc processes where it promotes their stabilization. This mechanism may be of importance in the increased formation of the myelin membrane induced by aTf.


Subject(s)
Apoproteins/pharmacology , Cytoskeleton/drug effects , Gene Expression Regulation/drug effects , Oligodendroglia/drug effects , Transferrin/pharmacology , Animals , Animals, Newborn , Blotting, Western/methods , Cells, Cultured , Cerebral Cortex/cytology , Cytochalasins/pharmacology , Cytoskeleton/metabolism , Gene Expression Regulation/physiology , Humans , Immunohistochemistry/methods , Microscopy, Confocal/methods , Microtubule-Associated Proteins/metabolism , Oligodendroglia/metabolism , Rats , Rats, Wistar , Receptors, Transferrin/metabolism , Tubulin/metabolism
20.
J Neurosci ; 23(11): 4635-44, 2003 Jun 01.
Article in English | MEDLINE | ID: mdl-12805303

ABSTRACT

We have used lactacystin, a specific inhibitor of the 26S proteasome, in oligodendroglial cell (OLGc) primary cultures to explore the possible participation of the proteasome-ubiquitin-dependent pathway in the decision of the OLGcs to arrest their proliferation and start differentiation. Addition of lactacystin at various concentrations to cultures containing a majority of OLGc was found to produce their withdrawal from the cell cycle and to induce their biochemical and morphological differentiation, with the appearance of extensive myelin-like sheets. The three classic proteolytic activities of the proteasome were significantly decreased in the lactacystin-treated cultures, and the immunocytochemical analysis showed an increase in the number of O4-, O1-, myelin basic protein-, and myelin proteolipid protein-positive cells and a decrease in A2B5-reacting cells. Quantitative immunochemical evaluation of the expression of certain proteins controlling the cell cycle showed an increase in p27kip1-, cyclin D-, and cdk4-positive cells, with a decrease in cyclin E- and cdk2-positive cells. In the lactacystin-treated OLGcs, there was a dose-dependent decrease in the number of cells incorporating bromodeoxyuridine and in the activity of the complexes cyclin D-cdk4 and cyclin E-cdk2. Furthermore, increased levels of expression of several STAT factors were found, suggesting that proteasome inhibition in OLGcs could stabilize signals of survival and differentiation that might be processed through the JAK/STAT signaling cascade.


Subject(s)
Acetylcysteine/analogs & derivatives , Acetylcysteine/pharmacology , Cell Differentiation/drug effects , Oligodendroglia/drug effects , Oligodendroglia/enzymology , Peptide Hydrolases/drug effects , Proteasome Endopeptidase Complex , Animals , Bromodeoxyuridine , Cell Cycle Proteins/biosynthesis , Cell Division/drug effects , Cell Survival/drug effects , Cells, Cultured , Cyclin-Dependent Kinases/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Dose-Response Relationship, Drug , Immunohistochemistry , Leupeptins/pharmacology , Macromolecular Substances , Oligodendroglia/cytology , Peptide Hydrolases/metabolism , Rats , Signal Transduction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...